RUA vs. NCYT, POLX, IHC, AVO, MHC, SUN, BELL, DEMG, NIOX, and SN
Should you be buying RUA Life Sciences stock or one of its competitors? The main competitors of RUA Life Sciences include Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), MyHealthChecked (MHC), Surgical Innovations Group (SUN), Belluscura (BELL), Deltex Medical Group (DEMG), NIOX Group (NIOX), and Smith & Nephew (SN). These companies are all part of the "medical devices" industry.
RUA Life Sciences vs.
RUA Life Sciences (LON:RUA) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.
In the previous week, Novacyt had 1 more articles in the media than RUA Life Sciences. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for RUA Life Sciences. Novacyt's average media sentiment score of 0.76 beat RUA Life Sciences' score of 0.00 indicating that Novacyt is being referred to more favorably in the news media.
RUA Life Sciences has higher earnings, but lower revenue than Novacyt. RUA Life Sciences is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.
Novacyt received 36 more outperform votes than RUA Life Sciences when rated by MarketBeat users. Likewise, 58.06% of users gave Novacyt an outperform vote while only 0.00% of users gave RUA Life Sciences an outperform vote.
RUA Life Sciences has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Novacyt has a beta of -1.86, indicating that its share price is 286% less volatile than the S&P 500.
RUA Life Sciences has a net margin of -65.72% compared to Novacyt's net margin of -203.06%. RUA Life Sciences' return on equity of -26.38% beat Novacyt's return on equity.
26.0% of RUA Life Sciences shares are held by institutional investors. Comparatively, 0.1% of Novacyt shares are held by institutional investors. 51.3% of RUA Life Sciences shares are held by insiders. Comparatively, 3.1% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
RUA Life Sciences beats Novacyt on 9 of the 15 factors compared between the two stocks.
Get RUA Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RUA Life Sciences Competitors List
Related Companies and Tools
This page (LON:RUA) was last updated on 5/2/2025 by MarketBeat.com Staff
Buy RUA Stock Free RUA Stock Alerts